Fms-Living Center in Fairport, New York - Dialysis Center

Fms-Living Center is a medicare approved dialysis facility center in Fairport, New York and it has 4 dialysis stations. It is located in Monroe county at 6687 Pittsford Palmyra Road, Ste 38, Fairport, NY, 14450. You can reach out to the office of Fms-Living Center at (585) 421-9839. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fms-Living Center has the following ownership type - Profit. It was first certified by medicare in May, 2002. The medicare id for this facility is 332630 and it accepts patients under medicare ESRD program.

Name	Fms-Living Center
Location	6687 Pittsford Palmyra Road, Ste 38, Fairport, New York
No. of Dialysis Stations	4
Medicare ID	332630
Managed By	Fresenius Medical Care
Ownership Type	Profit
Late Shifts	No

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Fms-Living Center from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

Dialysis patients with Hemoglobin data

4

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

• Hemodialysis

  Adult patients getting regular hemodialysis at the center	8
  Adult patient months included in Kt/V greater than or equal to 1.2	29
  Percentage of adult patients getting regular hemodialysis at the center
  Percentage of pediatric patients getting regular hemodialysis at the center

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fms-Living Center with elevated calcium levels.

Patients with hypercalcemia	9
Hypercalcemia patient months	38
Hypercalcemia patients with serumcalcium greater than 10.2 mg
Patients with Serumphosphor	12
Patients with Serumphosphor less than 3.5 mg/dL	29
Patients with Serumphosphor from 3.5 to 4.5 mg/dL	22
Patients with Serumphosphor from 4.6 to 5.5 mg/dL	24
Patients with Serumphosphor from 5.6 to 7 mg/dL	20
Patients with Serumphosphor greater than 7 mg/dL	4

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries	9
Patient months included in arterial venous fistula and catheter summaries	27
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer

The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.

Standard Hospitalization Summary Ratio(SHR) Year	January, 2016 - December, 2016
Patients in facility's Hospitalization Summary	6
Hospitalization Rate in facility	(Not Available)
Hospitalization Rate: Upper Confidence Limit
Hospitalization Rate: Lower Confidence Limit